期刊文献+

LMPs特异性T淋巴细胞对鼻咽癌细胞的杀伤作用

The cytotoxic effect of LMPs specific T lymphocytes on nasopharyngeal carcinoma cells
原文传递
导出
摘要 目的:研究树突状细胞负载EB病毒潜伏膜蛋白(latent membrane proteins,LMPs)介导生成的LMPs特异性细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)LMPs-CTL的生物学特性,观察其对LMPs阳性鼻咽癌细胞SUNE的杀伤作用。方法:用淋巴细胞分离液分离人外周血单核细胞,采用贴壁分离及白细胞介素(interleukin,IL)-4、粒细胞-巨噬细胞集落刺激因子(granulocyte-macrophage colony stimulating factor,GM-CSF)等细胞因子诱导成熟树突状细胞(dendritic cell,DC),通过DC细胞负载LMPs多肽抗原并递呈给同源T淋巴细胞,制备LMPs-CTL。CCK8法检测LMPs-CTL对SUNE细胞的杀伤作用;ELISA和羟基荧光素二醋酸盐琥珀酰亚胺脂(carboxy fluoroscein succinimidyl ester,CFSE)染色法检测LMPs-CTL分泌IFN-γ及其增殖。结果:LMPsCTL对SUNE细胞的杀伤率在12 h和24 h分别为(43.47±1.93)%和(77.15±3.18)%,显著高于对照组的(11.45±3.06)%和(24.27±13.20)%(P<0.05)。SUNE细胞刺激后,LMPs-CTL增殖能力较对照组有明显增强,IFN-γ分泌量达到(613.40±121.77)pg/ml,显著高于对照组(86.90±3.70)pg/ml(P<0.05)。结论:通过DC细胞负载LMPs混合多肽可诱导生成LMPsCTL,对LMPs阳性鼻咽癌细胞有较强的杀伤作用。 Objective:To study the biological characteristics of cytotoxic T lymphocyte(CTL) originated from dendritic cells(DC)loaded with the Epstein-Birr virus latent membrane proteins(LMPs),and to detect the cytotoxic effect of LMPs-CTL on the LMPs positive nasopharyngeal carcinoma cell SUNE.Methods:The mononuclear cells were isolated from human peripheral blood by lymphocyte separation medium.The adherent method was performed.Cytokines of IL-4 and GM-CSF were performed to induce mature DC.Loaded with LMPs polypeptide antigen,the mature DC presented antigen to autologous T lymphocyte for preparation of LMPsCTL.The cytotoxic effect of LMPs-CTL on SUNE cells was detected by the CCK8 method.The secretion of interferon-γ(IFN-γ) of LMPs-CTL and cell proliferation was detected by ELISA and carboxy fluoroscein succinimidyl ester(CFSE),respectively.Results:The killing efficiency of LMPs-CTL for SUNE was(43.47 ± 1.93)% in 12h and(77.15 ± 3.18)% in 24 h,which were higher than those in the control group[(11.45 ± 3.06)% and(24.27 ± 13.2)%(P〈 0.05)].The ability of LMPs-CTL cell proliferation simulated with SUNE cells was stronger than that in the control group.The IFN-γ secretion level secreted by LMPs-CTL was(613.40 ± 121.77)pg/ml,which was significantly higher than that secreted by the control group(86.90 ± 3.70) pg/ml(P〈 0.05).Conclusion:LMPs specific CTL can be successfully induced by mature DC and possess preferable specific killing activity on LMPs positive nasopharyngeal carcinoma cells.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2014年第6期705-710,共6页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省临床医学科技专项(BL2013038) 江苏省普通高校研究生科研创新计划(CXZZ12_0563)
关键词 EB病毒 潜伏膜蛋白 树突状细胞 细胞毒性T细胞 鼻咽癌 细胞免疫治疗 Epstein-birr virus latent membrane proteins dendritic cell cytotoxic T lymphocyte nasopharyngeal carcinoma cell immunotherapy
  • 相关文献

参考文献20

  • 1Yashin DV,Sashchenko LP,Kabanova OD,et al. The CD8^+ population of LAK cells can lyse both HLA-positive and HLA-negative cancer cell lines[J]. Dokl Biol Sci, 2009,426 : 296-297.
  • 2Sebastian M,Passlick B, Friccius-Quecke H,et al. Treat- ment of non-small cell lung cancer patients with the tri- functional monoclonal antibody catumaxomab (anti-Ep- CAM x anti-CD3):a phase I study[J]. Cancer Immunol Immunother, 2007,56(10) : 1637-1644.
  • 3匡志鹏,梁安民.CIK细胞联合树突状细胞治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,14(2):240-242. 被引量:22
  • 4Yao Y,Chen L,Wei W,et al. Tumor cell-derived exo- some-targeted dendritic cells stimulate stronger CD8^+ CTL responses and antitumor immunities[J]. Biochem Biophys Res Commun, 2013,436 ( 1 ) : 60-65.
  • 5Haque T,Wilkie GM,Jones MM,et al. Allogeneic cyto- toxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease:results of a phase 2 multi- center clinical trial[J]. Blood, 2007,110(4) : 1123-1131.
  • 6Icheva V, Kayser S,Wolff D,et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoprolif- erative disorders after allogeneic stem-cell transplantation [J]. J Clin Oncol,2013,31 (1) : 39-48.
  • 7Basso S,Zecca M,Merli P,et al. T cell therapy for na- sopharyngeal carcinoma [ J ]. J Cancer, 2011,2 : 341-346.
  • 8Pan J,Zhang Q,Zhou J,et al. Recombinant adeno-associ- ated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vac- cine for nasopharyngeal carcinoma[J]. Mol Cancer Ther, 2009,8(9) :2754-2761.
  • 9Smith C,Tsang J, Beagley L,et al. Effective treatment of met astatic forms of Epstein-Barr virus-associated na- sopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy [J]. Cancer Res,2012,72 (5) : 1116-1125.
  • 10Zhang D,Mao Y,Xiong L,et al. Characterization of hu- man Fab antibody fragments specific to LMP1 (HLEAFab) in nasopharyngeal carcinoma for potential molecular diagnosis and therapeutic applications[J]. On- col Lett,2013,5(5) : 1694-1698.

二级参考文献34

  • 1唐发清,尹楚南,张慈英,贺明伟.五类肿瘤患者细胞免疫功能调查[J].湖南医科大学学报,1996,21(4):355-357. 被引量:7
  • 2Hui Zheng Lili Li Duosha Hu Xiyun Deng Ya Cao.Role of Epstein-Barr Virus Encoded Latent Membrane Protein 1 in the Carcinogenesis of Nasopharyngeal Carcinoma[J].Cellular & Molecular Immunology,2007,4(3):185-196. 被引量:33
  • 3沈关心.现代免疫学实验技术(第2版)[M].湖北:科学技术出版社,2002.41-63.
  • 4Schuler G, Steinman R M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med,1997,186:1183-i187.
  • 5Auffermann-Gretzinger S, Keeffe E B, Levy S. Impaired dendritic cell maturation in patients with chronic,but not resolved, hepatitis C virus infection. Blood,2001,97:3171-3176.
  • 6Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods, 1999,223 : 1- 15.
  • 7Nestle F O,Alijagic S ,Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998,4 : 328- 332.
  • 8De Vries I J, Krooshoop D J , Scharenborg N M, et al.Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res, 2003,63 : 12- 17.
  • 9Cao X,Sugita M, Van Der Wel N, et al. CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class Ⅱ during dendritic cell maturation. J Immunol, 2002, 169:4770 -4777.
  • 10Coventry B J, Lee P L, Gibbs D, et al. Dendritic cell density and activation status in human breast cancer -CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer, 2002,86:546-551.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部